3.30
Miastenia Gravis II: Fisiopatologia
Il processo patologico della miastenia gravis inizia alla giunzione neuromuscolare, dove gli anticorpi attaccano proteine chiave necessarie all'attiva…
La Miastenia Gravis è una malattia autoimmune che interrompe la comunicazione tra nervi e muscoli.
In questa condizione, il sistema immunitario produce anticorpi contro componenti della membrana postsinaptica alla giunzione neuromuscolare, più comunemente recettori dell'acetilcolina.
Questi recettori sono essenziali per ricevere i segnali che innescano la contrazione muscolare.
Quando gli anticorpi bloccano i recettori, il segnale nervoso diventa troppo debole e il muscolo non può contrarsi efficacemente.
Di conseguenza, si sviluppa debolezza muscolare, soprattutto dopo un uso ripetuto, ma spesso migliora con il riposo.
Negli individui che non possiedono anticorpi contro i recettori dell'acetilcolina, il sistema immunitario può invece colpire altre proteine coinvolte nella comunicazione nervo-muscolo, come la chinasi specifica muscolare, essenziale per organizzare i recettori dell'acetilcolina alla giunzione neuromuscolare.
La ghiandola timo, che svolge un ruolo chiave nella regolazione immunitaria, è spesso anomala negli individui con Miastenia Gravis.
Può essere ipertrofia o contenere un tumore chiamato timoma, e si ritiene che abbia un ruolo nell'attivare la risposta autoimmune.
View the full transcript and gain access to JoVE Core videos
Q1: What causes muscle weakness in myasthenia gravis?
In myasthenia gravis, the immune system produces antibodies that block acetylcholine receptors on the postsynaptic membrane at the neuromuscular junction. These receptors normally receive signals that trigger muscle contraction. When antibodies block them, nerve signals become too weak to activate muscles effectively, causing progressive muscle weakness, especially after repeated use.
Q2: How do antibodies damage the neuromuscular junction in myasthenia gravis?
Antibodies targeting acetylcholine receptors not only block acetylcholine binding but also activate complement proteins, which damage the postsynaptic membrane and destroy receptor sites. Over time, the muscle end plate flattens and the number of functional receptors decreases by nearly 90%, reducing the strength of each nerve impulse and causing rapid muscle fatigue.
Q3: What happens when antibodies target muscle-specific kinase instead of acetylcholine receptors?
Some patients develop antibodies against muscle-specific kinase (MuSK) or lipoprotein-related protein 4 (LRP4), molecules that organize and stabilize acetylcholine receptors. When these proteins are attacked, receptors cannot cluster properly, disrupting nerve-muscle communication. Patients with these antibodies often experience prominent bulbar weakness, affecting swallowing and speech.
Q4: Why is the thymus gland involved in myasthenia gravis pathophysiology?
The thymus gland regulates immune cell development, but in myasthenia gravis it often becomes enlarged or contains a thymoma. Abnormal thymic tissue produces immune cells that mistakenly recognize acetylcholine receptor proteins as foreign, sustaining production of harmful antibodies. Removing the thymus often reduces symptoms or induces remission, especially in generalized cases.
Q5: How does myasthenia gravis differ from other neuromuscular disorders?
Myasthenia gravis is an autoimmune disorder specifically targeting the neuromuscular junction, whereas conditions like alterations in muscle tone involve different mechanisms affecting motor control. Unlike degenerative disorders, myasthenia gravis involves immune-mediated damage to receptors and supporting proteins, causing reversible weakness that improves with rest.
Q6: Why does muscle weakness in myasthenia gravis worsen with activity and improve with rest?
Repeated nerve stimulation depletes acetylcholine stores and exhausts the remaining functional receptors. Since antibodies have already reduced receptor numbers by up to 90%, fewer receptors are available to respond to subsequent signals. Rest allows acetylcholine to replenish and receptors to recover, temporarily restoring muscle function until activity resumes.
Q7: What role does complement activation play in myasthenia gravis pathophysiology?
When antibodies bind to acetylcholine receptors, they activate complement proteins, which directly damage the postsynaptic membrane and destroy receptor sites. This complement-mediated destruction accelerates the loss of functional receptors, contributing to the progressive weakening of neuromuscular transmission and the characteristic muscle fatigue seen in the disease.